lisaftoclax   Click here for help

GtoPdb Ligand ID: 13108

Synonyms: APG-2575 | APG2575
Compound class: Synthetic organic
Comment: Lisaftoclax (APG-2575) is an investigational oral BCL2 apoptosis regulator (BCL-2) inhibitor that was designed for antitumour activity [2]. It induces synthetic lethality in diffuse large B-cell lymphoma models when combined with the BTK inhibitor ibrutinib [2]. Synergy between lisaftoclax-mediated BCL2 inhibition and FLT3 kinase inhibition (olverembatinib) has been observed in acute myeloid leukemia models [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 12
Hydrogen bond donors 3
Rotatable bonds 14
Topological polar surface area 185.35
Molecular weight 882.43
XLogP 5.17
No. Lipinski's rules broken 4
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1CC2(C1)CCC(=C(C2)C3=CC=C(C=C3)Cl)CN4CCN(CC4)C5=CC=C(C(=C5)OC6=CC7=C(NC=C7)N=C6)C(=O)NS(=O)(=O)C8=CC=C(C(=C8)[N+](=O)[O-])NC[C@H]9COCCO9
Isomeric SMILES C1CC2(C1)CCC(=C(C2)C3=CC=C(C=C3)Cl)CN4CCN(CC4)C5=CC(=C(C=C5)C(=O)NS(=O)(=O)C6=CC(=C(C=C6)NC[C@H]7COCCO7)[N+](=O)[O-])OC8=CN=C9C(=C8)C=CN9
InChI InChI=1S/C45H48ClN7O8S/c46-33-4-2-30(3-5-33)39-25-45(12-1-13-45)14-10-32(39)28-51-16-18-52(19-17-51)34-6-8-38(42(23-34)61-35-22-31-11-15-47-43(31)49-26-35)44(54)50-62(57,58)37-7-9-40(41(24-37)53(55)56)48-27-36-29-59-20-21-60-36/h2-9,11,15,22-24,26,36,48H,1,10,12-14,16-21,25,27-29H2,(H,47,49)(H,50,54)/t36-/m0/s1
InChI Key FNBXDBIYRAPDPI-BHVANESWSA-N
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
BCL2 apoptosis regulator Hs Inhibitor Inhibition >10.0 pKi - 2
pKi >10.0 (Ki <1x10-10 M) [2]
Bcl-2-like 1 Hs Inhibitor Inhibition >9.3 pKi - 2
pKi >9.3 (Ki <5x10-10 M) [2]